BPC-157 comes up constantly in sourcing discussions — but the mechanism and research behind it rarely gets explained properly. I went through the published literature to build a proper reference and wanted to share what it actually says. What BPC-157 actually is: It's a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in human gastric juice. First isolated at the University of Zagreb in the 1990s. It's been studied consistently since then - a 2026 bibliometric review noted a clear upward trend in publications from 2010 through 2025, spanning musculoskeletal, gastrointestinal, and neurovascular research. Almost all of this research is preclinical. Rodent models, primarily. Keep that in mind. Why it works across so many tissue types - the actual mechanisms: Most forum discussions treat BPC-157 like a magic recovery compound without explaining why it does what it does. The research points to four overlapping mechanisms: 1. Angiogenesis - BPC-157 upregulates VEGFR2 and promotes new blood vessel formation in injured tissue. This is probably its most important mechanism. Tendons and ligaments have terrible blood supply naturally - that's why they heal slowly. BPC-157 improves the delivery system. 2. FAK-paxillin pathway activation - A 2010 study in the Journal of Physiology found BPC-157 activates this signalling pathway, which drives cell migration and survival. In tendon research specifically: it significantly accelerated fibroblast outgrowth from tendon explants and improved cell survival under stress. 3. GH receptor upregulation - Research in the Journal of Orthopaedic Research found BPC-157 increases growth hormone receptor expression in tendon fibroblasts. It sensitizes tissue to GH. This is why it stacks mechanistically well with GH-releasing peptides. 4. Nitric oxide modulation - It counteracts NO's damaging actions while preserving protective functions. This contributes to the cytoprotective effects across multiple organ systems. What the research actually shows by tissue: